Randomized controlled trials such as CHOIR [26] or CREATE [27] showed that targeting Hb to normal ranges in CKD patients or on HD (Normal Hematocrit Trial) [28] could be harmful and should be avoided. The gene discussed is GSTM1; the disease is chronic kidney disease.